Aspira Women’s Health Inc. is excited to announce a successful funding round that raised $1,370,000, a significant step in advancing our mission to transform women’s gynecological health. With a commitment to discovering, developing, and commercializing innovative diagnostic solutions, our company uses this fresh capital to further enhance our portfolio of cutting-edge tests designed specifically for women of all races and ethnicities. This funding will accelerate the continued development and marketing of our flagship ovarian cancer risk assessment tools, including OvaSuite℠, which integrates OvaWatch℠– a revolutionary, non-invasive, blood-based test. OvaWatch℠is transforming clinical practices by offering a negative predictive value of 99%, thereby empowering healthcare providers to confidently rule out ovarian malignancy in women with benign or indeterminate adnexal masses, and ultimately aiding in more precise patient management.
In addition, the investment will bolster the growth of our FDA-cleared Ova1Plus® product, combining Ova1® and Overa®, to detect ovarian malignancy risk among women scheduled for surgery. Moreover, we remain dedicated to pushing the boundaries of early diagnostics with the development of EndoCheck℠, our pioneering non-invasive test for endometriosis. This comprehensive funding round not only underlines investor confidence in our innovative approach but also reinforces our commitment to bridging the gap in women’s healthcare diagnostics. As we chart the next phase of growth, Aspira Women’s Health is poised to reach more patients and provide clinicians with the timely, actionable insights necessary to improve outcomes. For more information about our technology and ongoing projects, please visit our website at www.aspirawh.com.
